Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 23;7(10):1987-1990.
doi: 10.1182/bloodadvances.2022008574.

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease

Georg Gelbenegger  1 , Ulrich Jäger  2 , Michael Fillitz  3 , Christian Schörgenhofer  1 , Christian Sillaber  2 , Bernd Jilma  1
Affiliations

Sustained hematologic remission after discontinuation of sutimlimab treatment in patients with cold agglutinin disease

Georg Gelbenegger et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: G.G. was supported by the Austrian Science Funds (grant number SFB54-P04). B.J. received reimbursement for travel costs and scientific advice from Bioverativ and Sanofi. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Sustained hematologic remission after discontinuation of long-term treatment with sutimlimab. Time course of hemoglobin and bilirubin levels of the 3 included patients is shown for 3 phases: (i) washout from the NPP, (ii) long-term treatment with sutimlimab in the extension trial (abridged), and (iii) follow up after discontinuation of sutimlimab treatment. (i) The planned drug washout after end of the NPP induced the expected hemolysis in all 3 patients. (ii) Initiation of sutimlimab rapidly abrogated hemolysis and increased hemoglobin levels in all patients. (iii) In patients 1 and 2, steady near normal hemoglobin levels were observed for up to 12 months following discontinuation of sutimlimab. Bilirubin levels remained within the normal range in patient 1 and showed a small increase just above the normal range in patient 2. Patient 3 relapsed and developed transfusion-dependent anemia around 7 to 8 weeks after the last dose of sutimlimab. RBC, red blood cells.
See this image and copyright information in PMC

References

    1. Berentsen S, Barcellini W, D'Sa S, et al. Cold agglutinin disease revisited: a multinational, observational study of 232 patients. Blood. 2020;136(4):480–488. - PubMed
    1. Jäger U, Barcellini W, Broome CM, et al. Diagnosis and treatment of autoimmune hemolytic anemia in adults: recommendations from the First International Consensus Meeting. Blood Rev. 2020;41:100648. - PubMed
    1. Bylsma LC, Gulbech Ording A, Rosenthal A, et al. Occurrence, thromboembolic risk, and mortality in Danish patients with cold agglutinin disease. Blood Adv. 2019;3(20):2980–2985. - PMC - PubMed
    1. Jaffe CJ, Atkinson JP, Frank MM. The role of complement in the clearance of cold agglutinin-sensitized erythrocytes in man. J Clin Invest. 1976;58(4):942–949. - PMC - PubMed
    1. Shi J, Rose EL, Singh A, et al. TNT003, an inhibitor of the serine protease C1s, prevents complement activation induced by cold agglutinins. Blood. 2014;123(26):4015–4022. - PubMed

Publication types

MeSH terms

Substances